REGENXBIO Inc.
RGNX
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. Tā¦ read more
Healthcare
Biotechnology
10 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$14.59
Price+8.00%
$1.08
1Y
Price
Market Cap
$738.536m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-151.0%
EBITDA Margin-208.3%
Net Profit Margin-189.9%
Free Cash Flow MarginRevenue
$161.318m
+93.6%
1y CAGR+22.0%
3y CAGR-2.5%
5y CAGREarnings
-$177.915m
+21.7%
1y CAGR+13.8%
3y CAGR-69.4%
5y CAGREPS
-$3.47
+24.4%
1y CAGR+18.5%
3y CAGR-67.0%
5y CAGRBook Value
$161.452m
$525.203m
Assets$363.751m
Liabilities$268.140m
DebtDebt to Assets
51.1%
-2.2x
Debt to EBITDAFree Cash Flow
-$106.282m
+39.5%
1y CAGR+22.2%
3y CAGR-52.5%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company